We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$10.1B
$17.6M 1.18%
+442,000
New +$17.3M
RCM
27
DELISTED
R1 RCM Inc. Common Stock
RCM
$17.1M 1.14%
+770,000
New +$18.6M
HQY icon
28
HealthEquity
HQY
$7.97B
$15.9M 1.06%
+197,500
New +$15M
AMN icon
29
AMN Healthcare
AMN
$1.34B
$15.4M 1.03%
+159,101
New +$13.8M
OMCL icon
30
Omnicell
OMCL
$1.51B
$14.9M 0.99%
+98,366
New +$13.7M
MCK icon
31
McKesson
MCK
$104B
$14.4M 0.96%
75,000
-47,983
-39% -$9.27M
XBI icon
32
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$13.5M 0.9%
+100,000
New +$13.1M
TARO
33
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$12.5M 0.84%
174,249
+9,871
+6% +$725K
ARKK icon
34
ARK Innovation ETF
ARKK
$6.46B
$11.1M 0.74%
85,000
+3,000
+4% +$350K
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$137B
$11M 0.73%
+54,500
New +$11.4M
CI icon
36
Cigna
CI
$73.7B
$9.9M 0.66%
41,745
+1,745
+4% +$436K
MGLN
37
DELISTED
Magellan Health Services, Inc.
MGLN
$9.86M 0.66%
104,700
– –
TIP icon
38
PUT
iShares TIPS Bond ETF
TIP
$15B
$8.96M 0.6%
+70,000
New +$8.89M
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$31.7B
$8.67M 0.58%
51,136
-29,801
-37% -$4.36M
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
$8.57M 0.57%
495,860
-327,369
-40% -$6.02M
HUM icon
41
Humana
HUM
$46.3B
$8.27M 0.55%
18,656
-6,183
-25% -$2.7M
TDOC icon
42
CALL
Teladoc Health
TDOC
$1.18B
$6.65M 0.44%
+40,000
New +$6.48M
HZNP
43
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.55M 0.44%
+70,000
New +$6.44M
OPCH icon
44
Option Care Health
OPCH
$3.58B
$6.33M 0.42%
+289,297
New +$5.58M
OM icon
45
Outset Medical
OM
$74.1M
$5.36M 0.36%
+7,153
New +$5.47M
CNC icon
46
Centene
CNC
$32B
$4.96M 0.33%
68,000
-23,120
-25% -$1.58M
SRGA
47
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$4.91M 0.33%
129,403
+41,410
+47% +$2.12M
AFMD
48
DELISTED
Affimed
AFMD
$4.82M 0.32%
56,694
-47,919
-46% -$4.37M
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.79M 0.32%
117,462
-183,125
-61% -$6.77M
GSK icon
50
GSK
GSK
$102B
$4.61M 0.31%
90,143
-591,622
-87% -$28.4M
1
2
3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.